Publikation

Management of perimesencephalic nonaneurysmal subarachnoid hemorrhage: a national survey.

Wissenschaftlicher Artikel/Review - 07.08.2023

Bereiche
PubMed
DOI
Kontakt

Zitation
Wolfert C, Maurer C, Sommer B, Steininger K, Motov S, Bonk M, Krauss P, Berlis A, Shiban E. Management of perimesencephalic nonaneurysmal subarachnoid hemorrhage: a national survey. Sci Rep 2023; 13:12805.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Sci Rep 2023; 13
Veröffentlichungsdatum
07.08.2023
eISSN (Online)
2045-2322
Seiten
12805
Kurzbeschreibung/Zielsetzung

Perimesencephalic nonaneurysmal subarachnoid hemorrhage (NASAH) is a rare type of subarachnoid hemorrhage (SAH), usually associated with minor complications compared to aneurysmal SAH. Up to date, data is scarce and consensus on therapeutic management and follow-up diagnostics of NASAH is often missing. This survey aims to evaluate the clinical management among neurosurgical departments in Germany. 135 neurosurgical departments in Germany received a hardcopy questionnaire. Encompassing three case vignettes with minor, moderate and severe NASAH on CT-scans and questions including the in-hospital treatment with initial observation, blood pressure (BP) management, cerebral vasospasm (CV) prophylaxis and the need for digital subtraction angiography (DSA). 80 departments (59.2%) answered the questionnaire. Whereof, centers with a higher caseload state an elevated complication rate (Chi < 0.001). Initial observation on the intensive care unit is performed in 51.3%; 47.5%, 70.0% in minor, moderate and severe NASAH, respectively. Invasive BP monitoring is performed more often in severe NASAH (52.5%, 55.0%, 71.3% minor, moderate, severe). CV prophylaxis and transcranial doppler ultrasound (TCD) are performed in 41.3%, 45.0%, 63.8% in minor, moderate and severe NASAH, respectively. Indication for a second DSA is set in the majority of centers, whereas after two negative ones, a third DSA is less often indicated (2nd: 66.2%, 72.5%, 86.2%; 3rd: 3.8%, 3.8%, 13.8% minor, moderate, severe). This study confirms the influence of bleeding severity on treatment and follow-up of NASAH patients. Additionally, the existing inconsistency of treatment pathways throughout Germany is highlighted. Therefore, we suggest to conceive new treatment guidelines including this finding.